Investigational drugs in development for hypertriglyceridemia: a coming-of-age story

References

• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update a report from the american heart association. Circulation. 2017;135(10):e146–e603.
   PubMed Web of Science ®Google Scholar
• Rhainds D, Brodeur MR, Tardif JC. Lipids, apolipoproteins, and inflammatory biomarkers of cardiovascular risk: what have we learned? Clin Pharmacol Ther. 2018;104(2):244–256.
   PubMed Web of Science ®Google Scholar
• Quispe R, Hendrani A, Baradaran-Noveiry B, et al. Characterization of lipoprotein profiles in patients with hypertriglyceridemic fredrickson-levy and lees dyslipidemia phenotypes: the very large database of lipids studies 6 and 7. Arch Med Sci. 2019;15(5):1195–1202.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Ban MR, Hsueh N, et al. A polygenic basis for four classical fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet. 2009;18(21):4189–4194.
   PubMed Web of Science ®Google Scholar
• Carroll MD, Kit BK, Lacher DA, et al. Trends in lipids and lipoproteins in US adults, 1988–2010. JAMA. 2012;308(15):1545–1554.
   PubMed Web of Science ®Google Scholar
• Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in statin-treated US adults: the National health and nutrition examination survey. J Clin Lipidol. 2019;13(1):100–108.
   PubMed Web of Science ®Google Scholar
• Rosinger A, Carroll MD, Lacher D, et al. Trends in total cholesterol, triglycerides, and low-density lipoprotein in US adults, 1999–2014. JAMA Cardiol. 2017;2(3):339–341.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. Esc/eas Guidelines for the management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur Heart J. 2019;290:140–205.
   Google Scholar
• Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634–1639.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e1143.
   PubMed Web of Science ®Google Scholar
• Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol. 2019;13(1):80–88.
   PubMed Web of Science ®Google Scholar
• Dron JS, Wang J, McIntyre AD, et al. Partial LPL deletions: rare copy-number variants contributing towards the polygenic form of severe hypertriglyceridemia. J Lipid Res. 2019;60:1953–1958.
   PubMed Web of Science ®Google Scholar
• Karanchi H, Wyne K, Hypertriglyceridemia, in StatPearls. 2019: Treasure Island (FL).
   Google Scholar
• Pedersen SB, Varbo A, Langsted A, et al. Chylomicronemia risk factors ranked by importance for the individual and community in 108 711 women and men. J Intern Med. 2018;283(4):392–404.
   PubMed Web of Science ®Google Scholar
• de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis: epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018;6(5):649–655.
   PubMed Web of Science ®Google Scholar
• Berberich AJ, Ziada A, Zou GY, et al. Conservative management in hypertriglyceridemia-associated pancreatitis. J Intern Med. 2019;286:644–650.
   PubMedGoogle Scholar
• Thomsen M, Varbo A, Tybjaerg-Hansen A, et al. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin Chem. 2014;60(5):737–746.
   PubMed Web of Science ®Google Scholar
• Jorgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34(24):1826–1833.
   PubMed Web of Science ®Google Scholar
• Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539–550.
   PubMed Web of Science ®Google Scholar
• Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118(4):579–585.
   PubMed Web of Science ®Google Scholar
• TG and HDL Working Group of the Exome Sequencing Project, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31.
   PubMed Web of Science ®Google Scholar
• Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32–41.
   PubMed Web of Science ®Google Scholar
• Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054–2063.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of angptl3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–221.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in angptl4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–1133.
   PubMed Web of Science ®Google Scholar
• Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators, Stitziel NO, Stirrups KE, et al. Coding variation in angptl4, lpl, and svep1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134–1144.
   PubMed Web of Science ®Google Scholar
• Baggio G, Manzato E, Gabelli C, et al. Apolipoprotein C-II deficiency syndrome. clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J Clin Invest. 1986;77(2):520–527.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69–76.
   PubMed Web of Science ®Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Robinson JG, Kowalewski M, et al. association between baseline ldl-c level and total and cardiovascular mortality after ldl-c lowering: a systematic review and meta-analysis. JAMA. 2018;319(15):1566–1579.
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724–730.
   PubMed Web of Science ®Google Scholar
• Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104(4):459–463.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65(21):2267–2275.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–458.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.
   PubMed Web of Science ®Google Scholar
• Ye X, Kong W, Zafar MI, et al. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019;18(1):48.
   PubMedGoogle Scholar
• Bezafibrate Infarction Prevention, s. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21–27.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med. 1999;341(6):410–418.
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285(12):1585–1591.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Scott R, Donoghoe M, Watts GF, et al. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol. 2011;10:102.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol. 2012;6(5):413–426.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–1361.
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088–2093.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692–694. author reply 694-5.
   PubMed Web of Science ®Google Scholar
• Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012;35(5):1008–1014.
   PubMed Web of Science ®Google Scholar
• Geng Q, Ren J, Chen H, et al. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Clin Exp Pharmacol Physiol. 2013;40(3):219–226.
   PubMed Web of Science ®Google Scholar
• Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006;5(1):145–156.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Abe K, Toma T, et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists. Bioorg Med Chem Lett. 2007;17(16):4689–4693.
   PubMed Web of Science ®Google Scholar
• Takei K, Han SI, Murayama Y, et al. Selective peroxisome proliferator-activated receptor-alpha modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-alpha pathway and improves lipid metabolism in mice. J Diabetes Investig. 2017;8(4):446–452.
   PubMed Web of Science ®Google Scholar
• Raza-Iqbal S, Tanaka T, Anai M, et al. Transcriptome analysis of K-877 (a novel selective PPARalpha modulator (SPPARMalpha))-regulated genes in primary human hepatocytes and the mouse liver. J Atheroscler Thromb. 2015;22(8):754–772.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Santos RD, Aguilar-Salinas C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha) paradigm: conceptual framework and therapeutic potential: A consensus statement from the international atherosclerosis society (ias) and the residual risk reduction initiative (R3i) foundation. Cardiovasc Diabetol. 2019;18(1):71.
   PubMed Web of Science ®Google Scholar
• Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low hdl cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25(6):521–538.
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36–43.
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Arai H, Yokote K, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12(1):173–184.
   PubMed Web of Science ®Google Scholar
• Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144–152.
   PubMed Web of Science ®Google Scholar
• Araki E, Yamashita S, Arai H, et al. Effects of pemafibrate, a novel selective α modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41(3):538–546.
   PubMed Web of Science ®Google Scholar
• Araki E, Yamashita S, Arai H, et al. Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. Diabetes Obes Metab. 2019;21(7):1737–1744.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93.
   PubMed Web of Science ®Google Scholar
• Baum SJ, Scholz KP. Rounding the corner on residual risk: implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. Clin Cardiol. 2019;42:829–838.
   Web of Science ®Google Scholar
• Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149.
   PubMed Web of Science ®Google Scholar
• Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387–393.
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Packard CJ, Boren J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep. 2019;21(8):27.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–690.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–992.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13(1):37–46.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10(3):635–645. e1.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial. Clin Cardiol. 2017;40(3):138–148.
   PubMed Web of Science ®Google Scholar
• Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS). Atherosclerosis. 2008;200(1):135–140.
   PubMed Web of Science ®Google Scholar
• Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99–107.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Stroes ESG. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380(1):89–90.
   PubMed Web of Science ®Google Scholar
• Gao L, Moodie M, Li SC. The cost-effectiveness of omega-3 polyunsaturated fatty acids - the Australian healthcare perspective. Eur J Intern Med. 2019;67:70–76.
   PubMed Web of Science ®Google Scholar
• Beckermann B, Beneke M, Seitz I. Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers. Arzneimittelforschung. 1990;40(6):700–704.
   PubMed Web of Science ®Google Scholar
• Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun. 1988;152(1):328–335.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Johnson J, Rooney MW, et al. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova((R)) compared to Lovaza((R)) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6(6):573–584.
   PubMed Web of Science ®Google Scholar
• Offman E, Marenco T, Ferber S, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013;9:563–573.
   PubMedGoogle Scholar
• Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the epanova for lowering very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8(1):94–106.
   PubMed Web of Science ®Google Scholar
• Morton AM, Furtado JD, Lee J, et al. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol. 2016;10(6):1442–1451. e4.
   PubMed Web of Science ®Google Scholar
• Stroes ESG, Susekov AV, de Bruin TWA, et al. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. J Clin Lipidol. 2018;12(2):321–330.
   PubMed Web of Science ®Google Scholar
• Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35(9):1400–11 e1-3.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Glickstein SB, Rowe JD, et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6(1):5–18.
   PubMed Web of Science ®Google Scholar
• Dunbar RL, Nicholls SJ, Maki KC, et al. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis. 2015;14:98.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41(10):1281–1288.
   PubMed Web of Science ®Google Scholar
• Gordts PL, Nock R, Son N-H, et al. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016;126(8):2855–2866.
   PubMed Web of Science ®Google Scholar
• Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322(5908):1702–1705.
   PubMed Web of Science ®Google Scholar
• Milonas D, Tziomalos K. Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia - spotlight on volanesorsen. Expert Opin Investig Drugs. 2019;28(4):389–394.
   PubMed Web of Science ®Google Scholar
• Post N, Yu R, Greenlee S, et al. Metabolism and disposition of volanesorsen, a 2’ MOE antisense oligonucleotide, across species. Drug Metab Dispos. 2019;47:1164–1173.
   PubMed Web of Science ®Google Scholar
• Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408–1415.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200–2206.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Bell TA, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479–1490.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Alexander VJ, Baker BF, et al. antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–447.
   PubMed Web of Science ®Google Scholar
• Blom DJ, O’Dea L, Digenio A, et al. Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study. J Clin Lipidol. 2018;12(5):1234–1243 e5.
   PubMed Web of Science ®Google Scholar
• Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531–542.
   PubMed Web of Science ®Google Scholar
• Arca M, Hsieh A, Soran H, et al. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Rev Cardiovasc Ther. 2018;16(7):537–546.
   PubMed Web of Science ®Google Scholar
• Koishi R, Ando Y, Ono M, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet. 2002;30(2):151–157.
   PubMed Web of Science ®Google Scholar
• Shan L, Yu X-C, Liu Z, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem. 2009;284(3):1419–1424.
   PubMed Web of Science ®Google Scholar
• Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220–2227.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296–297.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gusarova V, Banfi S, et al. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015;56(7):1296–1307.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470–486.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of angptl3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222–232.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Mattijssen F, de Wit NJ, et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010;12(6):580–592.
   PubMed Web of Science ®Google Scholar
• Desai U, Lee E-C, Chung K, et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci U S A. 2007;104(28):11766–11771.
   PubMed Web of Science ®Google Scholar
• Brahm AJ, Hegele RA. Lomitapide for the treatment of hypertriglyceridemia. Expert Opin Investig Drugs. 2016;25(12):1457–1463.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years’ treatment with lomitapide. JAMA Intern Med. 2014;174(3):443–447.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019 Aug 31. pii: ehz486. doi: 10.1093/eurheartj/ehz486.
   Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab. 2019;21(11):2576–2580.
   PubMed Web of Science ®Google Scholar
• Xiao C, Bandsma RHJ, Dash S, et al. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol. 2012;32(6):1513–1519.
   PubMed Web of Science ®Google Scholar
• Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010;212(1):217–222.
   PubMed Web of Science ®Google Scholar
• Verges B, Duvillard L, Pais de Barros JP, et al. Liraglutide reduces postprandial hyperlipidemia by increasing apob48 (apolipoprotein b48) catabolism and by reducing apob48 production in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2018;38(9):2198–2206.
   PubMed Web of Science ®Google Scholar
• Matikainen N, Söderlund S, Björnson E, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab. 2019;21(1):84–94.
   PubMed Web of Science ®Google Scholar
• Sawada T, Uzu K, Hashimoto N, et al. Empagliflozin’s ameliorating effect on plasma triglycerides: association with endothelial function recovery in diabetic patients with coronary artery disease. J Atheroscler Thromb. 2019. doi:10.5551/jat.50807.
   Google Scholar
• Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008;28(12):2303–2304.
   PubMed Web of Science ®Google Scholar
• Shukla V, Seoane-Vazquez E, Fawaz S, et al. The landscape of cellular and gene therapy products: authorization, discontinuations, and cost. Hum Gene Ther Clin Dev. 2019;30(3):102–113.
   PubMed Web of Science ®Google Scholar
• Blair HA. Pemafibrate: first global approval. Drugs. 2017;77(16):1805–1810.
   PubMed Web of Science ®Google Scholar
• Gusarova V, Banfi S, Alexa-Braun CA, et al. ANGPTL8 blockade with a monoclonal antibody promotes triglyceride clearance, energy expenditure, and weight loss in mice. Endocrinology. 2017;158(5):1252–1259.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the european atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459–2472.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wu J.H. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–2067.
   PubMed Web of Science ®Google Scholar
• Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98(4A):27i–33i.
   PubMed Web of Science ®Google Scholar
• Steinhagen-Thiessen E, Stroes E, Soran H, et al. The role of registries in rare genetic lipid disorders: review and introduction of the first global registry in lipoprotein lipase deficiency. Atherosclerosis. 2017;262:146–153.
   PubMed Web of Science ®Google Scholar
• Mazidi M, Katsiki N, Mikhailidis DP, et al. Association of empirical dietary atherogenic indices with all-cause and cause-specific mortality in a multi-ethnic adult population of the United States. Nutrients. 2019;11(10):2323.
   PubMedGoogle Scholar
• Yamanaka M, Sakuma M, Matsushita A, et al. The effects of long-term dietary therapy on patients with hypertriglyceridemia. J Atheroscler Thromb. 2019;26(1):39–49.
   PubMed Web of Science ®Google Scholar